GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » 3-Year FCF Growth Rate

CanSino Biologics (HKSE:06185) 3-Year FCF Growth Rate : -21.20% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics 3-Year FCF Growth Rate?

CanSino Biologics's Free Cash Flow per Share for the three months ended in Mar. 2024 was HK$-1.07.

During the past 12 months, CanSino Biologics's average Free Cash Flow per Share Growth Rate was -563.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -21.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of CanSino Biologics was -21.20% per year. The lowest was -104.30% per year. And the median was -33.15% per year.


Competitive Comparison of CanSino Biologics's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's 3-Year FCF Growth Rate falls into.



CanSino Biologics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


CanSino Biologics  (HKSE:06185) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


CanSino Biologics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (HKSE:06185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Executives
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Mao Helen Huihua 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Yu Xuefeng 2501 Other
Zhu Tao
Chao Shou Bai 2202 Interest of your spouse
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines